This cluster reflects a two-pronged research trajectory in Alzheimer's disease targeting the same clinical gap: detecting and intervening in preclinical/early-stage disease before overt cognitive decline. The first prong is diagnostic, centered on the maturation of blood-based biomarkers—plasma GFAP and circulating sphingomyelins alongside plasma T-tau—as minimally invasive substitutes for lumbar puncture and CSF-based testing. Plasma GFAP is shown to outperform CSF GFAP in detecting amyloid pathology and independently predicts clinical progression, positioning it as a validated tool for both diagnostic and prognostic stratification in early Alzheimer's disease. Sphingomyelins add a complementary lipidomic dimension: their levels correlate inversely with cortical amyloid-beta burden and positively with plasma T-tau specifically in amyloid-positive cognitively unimpaired individuals, and lower sphingomyelin levels track with weaker cognitive performance. Together these biomarkers suggest a convergent blood-based signature—combining glial injury (GFAP), tau pathology (T-tau), and lipid dysregulation (sphingomyelins)—that could enable earlier, more accessible identification of individuals on the Alzheimer's continuum, well before symptomatic thresholds are crossed.
The second prong is interventional, exploring transcranial vibrotactile stimulation (40 Hz and 80 Hz) as a non-pharmacological neuromodulation strategy to enhance memory in preclinical models. Mechanistically, this approach operates through frequency-dependent mechanotransduction, converting mechanical vibration into cellular signaling that enhances hippocampal cholinergic function—a system central to memory encoding and known to degrade early in Alzheimer's pathophysiology. Downstream, this cholinergic enhancement activates a canonical memory signaling cascade (PI3K–AKT–ERK1/2–CREB–CAMK4) alongside BDNF upregulation, collectively driving memory-related gene expression and measurable improvements in cognitive performance in mouse models. Both stimulation frequencies produced convergent benefits, suggesting a degree of mechanistic redundancy or complementary engagement of cholinergic-synaptic plasticity pathways.
The overarching narrative is one of a field bifurcating into "detect early, intervene early" strategies that could eventually be paired: blood biomarkers to identify at-risk, amyloid-positive but cognitively unimpaired individuals, and non-invasive neuromodulation as a scalable, drug-free intervention to bolster cholinergic and memory-consolidation pathways before neurodegeneration advances. Notably, the vibrotactile stimulation findings remain preclinical, with explicit acknowledgment that human validation is required before translation—paralleling how blood biomarker validation studies have already moved toward clinical qualification. This juxtaposition highlights a broader trend toward minimally invasive, mechanistically grounded tools spanning the diagnostic-to-therapeutic continuum in preclinical Alzheimer's disease, with cholinergic signaling and amyloid/tau-related pathology serving as shared biological anchors linking biomarker discovery to novel intervention design.